Auricular Fibrillation
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Boehringer IngelheimINGELHEIM, Germany
1 programDiscontinuation for Oral Anticoagulants in Patients With Atrial FibrillationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Boehringer IngelheimDiscontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
Clinical Trials (1)
Total enrollment: 360 patients across 1 trials
NCT04133545Boehringer IngelheimDiscontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
Start: Apr 2018Est. completion: Sep 2020360 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.